Contrave

Drug Overview

Contrave is a highly specialized, dual-action medication utilized within the Psychiatry and metabolic medicine fields. It belongs to the Opioid Antagonist + Antidepressant drug class. Recognizing that weight management is deeply tied to the brain’s neurochemistry, this medication was developed to target both the physical sensation of hunger and the psychological cravings associated with food addiction.

Here is a quick breakdown of the medication’s primary details:

• Generic Name: Naltrexone and Bupropion (Extended-Release)
• US Brand Names: Contrave® (Known as Mysimba® in European markets)
• Route of Administration: Oral (Extended-release tablet)
• FDA Approval Status: Fully FDA-Approved

What Is It and How Does It Work? (Mechanism of Action)

Contrave acts as a form of Targeted Therapy for the brain’s weight regulation and reward systems. It combines two distinct medications into a single tablet, creating a powerful synergy that alters how the brain perceives food and hunger.

To understand how it works at the molecular level, it helps to look at two specific areas of the brain: the hypothalamus (the appetite control center) and the mesolimbic dopamine circuit (the reward center).

• Bupropion (The Antidepressant Component): This medication increases the levels of two neurotransmitters—dopamine and norepinephrine—in the brain. By doing so, it stimulates a specific group of neurons in the hypothalamus called POMC neurons. When activated, POMC neurons strongly suppress appetite and increase energy expenditure.
• Naltrexone (The Opioid Antagonist Component): Normally, when POMC neurons are activated, the brain eventually tries to turn them off using its own natural opioids (endorphins) to maintain a baseline weight. Naltrexone specifically blocks the mu-opioid receptors. By blocking this natural “off switch,” naltrexone allows the appetite-suppressing POMC neurons to continue firing for a much longer period.
• The Synergy: Together, bupropion reduces hunger and food cravings, while naltrexone amplifies and prolongs that effect, helping patients feel full sooner and reducing the psychological reward of eating highly palatable (sweet or fatty) foods.

FDA-Approved Clinical Indications

Contrave is recognized globally as a vital tool for comprehensive weight management when combined with behavioral lifestyle changes.

Primary Psychiatric Indications

• Binge Eating Disorder (Off-Label): In psychiatric practice, the medication is frequently utilized off-label to control severe food cravings and reduce the frequency of binge eating episodes, given its direct action on the brain’s reward pathways.
• Comorbid Depression and Obesity (Off-Label): Used when patients require simultaneous management of depressive symptoms and weight reduction.

Off-Label / Neurological Indications

• Primary Indication: Chronic weight management in adults with an initial Body Mass Index (BMI) of 30 kg/m² or greater (obesity), or a BMI of 27 kg/m² or greater (overweight) in the presence of at least one weight-related condition (e.g., high blood pressure, type 2 diabetes, or high cholesterol).
• Smoking Cessation Support: Occasionally utilized off-label due to the bupropion component, which is a recognized treatment for nicotine withdrawal.

Dosage and Administration Protocols

Because Contrave affects brain chemistry, the dose must be increased gradually (titrated) over a four-week period to minimize stomach upset and allow the central nervous system to adjust.

Each tablet contains exactly 8 mg of naltrexone and 90 mg of bupropion.

Important Adjustments and Considerations:

• Hepatic (Liver) Impairment: Contrave is heavily processed by the liver. It is contraindicated (must not be used) in patients with severe liver disease. For mild to moderate liver impairment, the maximum daily dose is strictly limited to one tablet in the morning.
• Renal (Kidney) Impairment: For patients with moderate or severe kidney disease, the maximum dose is limited to two tablets daily (one in the morning, one in the evening). It should not be used in end-stage renal disease.

Clinical Efficacy and Research Results

Clinical data from extensive trials and ongoing registry data (2020-2026) validate Contrave’s efficacy as an adjunct to diet and exercise.

• Weight Loss Percentages: Across multiple large-scale clinical trials (such as the COR-I and COR-II studies), approximately 45% to 55% of patients taking Contrave achieved a clinically significant weight loss of 5% or more of their total body weight over a 52-week period.
• High Responders: Approximately 25% of patients are considered “high responders,” achieving a weight loss of 10% or more within the first year of treatment.
• Psychiatric and Behavioral Metrics: In off-label studies targeting Binge Eating Disorder, patients reported a 40% to 50% reduction in craving intensity on standard psychiatric eating questionnaires, alongside a significant decrease in weekly binge episodes.
• Cardiometabolic Improvements: The sustained weight loss frequently leads to notable improvements in HDL (“good”) cholesterol, triglycerides, and insulin resistance markers.

Safety Profile and Side Effects

BLACK BOX WARNING: > Suicidal Thoughts and Behaviors: Contrave contains bupropion, an antidepressant. Antidepressants can increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (under age 24). Patients of all ages must be monitored closely for sudden changes in mood, worsening depression, or unusual behaviors.

Common Side Effects (>10% incidence):

• Nausea: The most common side effect, affecting roughly 30% of patients, particularly during the dose-escalation phase.
• Constipation and dry mouth.
• Headaches and dizziness.
• Insomnia (trouble sleeping).

Serious Adverse Events:

• Seizures: Bupropion lowers the seizure threshold. The risk increases with higher doses or in patients with a history of seizures, eating disorders (bulimia or anorexia), or abrupt alcohol withdrawal.
• Increased Blood Pressure and Heart Rate: The medication can elevate resting heart rate and blood pressure, requiring regular monitoring.
• Opioid Overdose Risk: Because naltrexone blocks opioid receptors, a patient attempting to overcome this blockade by taking high doses of opioid pain medications could suffer a fatal overdose or severe respiratory depression.

Management Strategies:

Nausea is usually temporary and can be managed by following the slow 4-week titration schedule. If insomnia occurs, the evening dose should be taken earlier in the afternoon. If a patient experiences a seizure, severe allergic reaction, or sudden mood deterioration, the medication must be discontinued immediately.

Research Areas

While there is no direct link between Contrave and regenerative medicine or stem cell therapies, current research heavily explores its potential in Metabolic Psychiatry. Ongoing studies are investigating the overlapping neural pathways of severe food addiction and major depressive disorder. Researchers aim to understand if normalizing the brain’s dopamine reward circuitry with Contrave can simultaneously reverse obesity-induced neuro-inflammation and improve long-term cognitive and emotional resilience.

Disclaimer: The studies and findings described in the Research Areas section of this article are currently in exploratory and ongoing investigative phases and are not yet validated for clinical application or practical use in professional medical settings.

Patient Management and Practical Recommendations

Effective weight management requires a strong partnership between the patient and their healthcare provider, alongside strict adherence to safety guidelines.

Pre-treatment Tests Required:

• Baseline blood pressure and resting heart rate check.
• A thorough medical history review to rule out seizure disorders, eating disorders, and recent use of opioid medications or monoamine oxidase inhibitors (MAOIs).
• A mental health screening for bipolar disorder or active suicidal ideation.

Precautions During Treatment:

Patients must be entirely opioid-free for at least 7 to 10 days before starting Contrave. This includes certain cough medicines containing codeine or anti-diarrhea medicines.

Do’s and Don’ts:

• DO swallow the tablets whole; never crush, chew, or divide them, as this destroys the extended-release mechanism and increases seizure risk.
• DO combine the medication with a structured, reduced-calorie diet and an exercise program for maximum results.
• DO inform all your healthcare providers (including dentists) that you are taking a medication that blocks opioid pain relievers.
• DON’T take Contrave with a high-fat meal (like a heavy fast-food breakfast or cheese-heavy dinner), as dietary fat dramatically increases the absorption of the drug into the bloodstream, raising the risk of seizures and severe side effects.
• DON’T drink excessive alcohol, and do not stop drinking alcohol abruptly if you are a heavy drinker, as both actions significantly increase seizure risk.
• DON’T take other medications containing bupropion (such as Wellbutrin or Zyban) at the same time.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment plan. Never disregard professional medical advice or delay in seeking it because of something you have read here.